Phase I trial of novel allogeneic CAR T-cell therapy shows positive early results in metastatic ccRCC

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

FDA granted orphan drug designation to MB-105, March Biosciences’s first-in-class CD5-targeted CAR T-cell therapy, for the treatment of relapsed/refractory CD5-positive T-cell lymphoma.

February 07, 2025

Vol.51 No.05

Less taxing therapies taking center stage

Advances such as new nontoxic, more effective immunotherapy and improvements that significantly reduce recovery times for complicated surgeries are making cancer treatments less taxing. On the horizon are more ways to give patients the greatest chance of survival while also reducing negative consequences of treatment. Some therapies also will improve the experience, such as chemotherapy consisting of quick subcutaneous injections instead of hours in an infusion chair.

Scientists uncover protein that helps cancer cells dodge CAR T-cell therapy

Scientists at City of Hope identified a protein that could help prevent CAR T-cell therapy antigen escape. The research, published in the journal Cell, could lead to more personalized therapies that improve cancer patients’ survival.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Researchers from City of Hope, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and NIH have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor T-cell therapy resistance. The new system is outlined in a paper published in Nature Biomedical Engineering.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Nektar Therapeutics announced results of its phase II proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma at the 66th ASH Annual Meeting and Exposition in San Diego.

December 13, 2024

Vol.50 No.46

Phase I trial of novel allogeneic CAR T-cell therapy shows positive early results in metastatic ccRCC

YOU MAY BE INTERESTED IN

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

Less taxing therapies taking center stage

Scientists uncover protein that helps cancer cells dodge CAR T-cell therapy

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Renew today!

Subscriber content

Never miss an issue!

Login